Molecular framework for response to imatinib mesylate in systemic sclerosis

Arthritis and Rheumatism

Volumn 60, Issue 2, 2009, Pages 584-591

  Chung, Lorinda ^a,b   Fiorentino, David F ^a   BenBarak, Maya J ^a,b   Adler, Adam S ^a   Mariano, Melissa M ^a,b   Paniagua, Ricardo T ^a,b   Milano, Ausra ^c   Connolly, M Kari ^d   Ratiner, Boris D ^e   Wiskocil, Robert L ^f   Whitfield, Michael L ^c   Chang, Howard Y ^a,g   Robinson, William H ^a,b,g  

^a STANFORD UNIVERSITY   (United States)

^b VA PALO ALTO HEALTH CARE SYSTEM   (United States)

^c DARTMOUTH MEDICAL SCHOOL   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e Rheumatology Therapeutics Medical Center   (United States)

^f KAISER PERMANENTE   (United States)

^g STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABELSON KINASE; BENAZEPRIL; IMATINIB; IMMUNOGLOBULIN; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PLATELET DERIVED GROWTH FACTOR B; PREDNISONE;

ADULT; ARTHRITIS; ARTICLE; CASE REPORT; CELL PROLIFERATION; CLINICAL FEATURE; CONTROLLED STUDY; DRUG INHIBITION; DRUG MECHANISM; FEMALE; FIBROBLAST; GENE EXPRESSION PROFILING; HUMAN; HUMAN TISSUE; PATHOGENESIS; PRIORITY JOURNAL; RAYNAUD PHENOMENON; SKIN BIOPSY; SYSTEMIC SCLEROSIS; TREATMENT RESPONSE;

FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMANS; MIDDLE AGED; ONCOGENE PROTEINS V-ABL; PIPERAZINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR BETA; SCLERODERMA, DIFFUSE; SKIN; YOUNG ADULT;

EID: 59649118981     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.24221     Document Type: Article

References (16)

1. Baroni SS, Santillo M, Bevilacqua F, Luchetti M, Spadoni T, Mancini M, et al. Stimulatory autoantibodies to the PDGF receptor in systemic sclerosis. N Engl J Med 2006;354:2667-76.
2. Ludwicka A, Ohba T, Trojanowska M, Yamakage A, Strange C, Smith EA, et al. Elevated levels of platelet derived growth factor and transforming growth factor-β1 in bronchoalveolar lavage fluid from patients with scleroderma. J Rheumatol 1995;22:1876-83.
3. Yamakage A, Kikuchi K, Smith EA, LeRoy EC, Trojanowska M. Selective upregulation of platelet-derived growth factor receptors by transforming growth factor β in scleroderma fibroblasts. J Exp Med 1992;175:1227-34.
4. Schermuly RT, Dony E, Ghofrani HA, Pullamsetti S, Savai R, Roth M, et al. Reversal of experimental pulmonary hypertension by PDGF inhibition. J Clin Invest 2005;115:2811-21.
5. Soria A, Cario-Andre M, Lepreux S, Rezvani HR, Pasquet JM, Pain C, et al. The effect of imatinib (Glivec) on scleroderma and normal dermal fibroblasts: a preclinical study. Dermatology 2008;216:109-17.
6. Distler JH, Jungel A, Huber LC, Schulze-Horsel U, Zwerina J, Gay RE, et al. Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis. Arthritis Rheum 2007;56:311-22.
7. Daniels CE, Wilkes MC, Edens M, Kottom TJ, Murphy SJ, Limper AH, et al. Imatinib mesylate inhibits the profibrogenic activity of TGF-β and prevents bleomycin-mediated lung fibrosis. J Clin Invest 2004;114:1308-16.
8. Paniagua RT, Sharpe O, Ho PP, Chan SM, Chang A, Higgins JP, et al. Selective tyrosine kinase inhibition by imatinib mesylate for the treatment of autoimmune arthritis. J Clin Invest 2006;116:2633-42.
9. Souza R, Sitbon O, Parent F, Simonneau G, Humbert M. Long term imatinib treatment in pulmonary arterial hypertension. Thorax 2006;61:736.
10. Clements P, Lachenbruch P, Seibold J, White B, Weiner S, Martin R, et al. Inter and intraobserver variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis. J Rheumatol 1995;22:1281-5.
11. Chang HY, Nuyten DS, Sneddon JB, Hastie T, Tibshirani R, Sorlie T, et al. Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival. Proc Natl Acad Sci U S A 2005;102:3738-43.
12. Milano A, Pendergrass SA, Sargent JL, George LK, McCalmont TH, Connolly MK, et al. Molecular subsets in the gene expression signatures of scleroderma skin. PLoS ONE 2008;3:e2696.
13. Whitfield ML, Finlay DR, Murray JI, Troyanskaya OG, Chi JT, Pergamenschikov A, et al. Systemic and cell type-specific gene expression patterns in scleroderma skin. Proc Natl Acad Sci U S A 2003;100:12319-24.
14. Sfikakis PP, Gorgoulis VG, Katsiari CG, Evangelou K, Kostopoulos C, Black CM. Imatinib for the treatment of refractory, diffuse systemic sclerosis. Rheumatology (Oxford) 2008;47:735-7.
15. Rajkumar VS, Shiwen X, Bostrom M, Leoni P, Muddle J, Ivarsson M, et al. Platelet-derived growth factor-β receptor activation is essential for fibroblast and pericyte recruitment during cutaneous wound healing. Am J Pathol 2006;169:2254-65.
16. Del Papa N, Quirici N, Corti L, Graziani D, Fasoli E, Maglione W, et al. Clinical and molecular evidence for c-kit receptor as a therapeutic target in systemic sclerosis (SSc) [abstract]. Arthritis Rheum 2007;56 Suppl 9:S816.